Detail Information of Post-Translational Modifications

General Information of Drug Transporter (DT)
DT ID	DTD0111 Transporter Info
Gene Name	SLC16A7
Transporter Name	Monocarboxylate transporter 2
Gene ID	9194
UniProt ID	O60669

Post-Translational Modification of This DT
Overview ofSLC16A7 Modification Sites with Functional and Structural Information
Sequence	M P P M P S A P P V H P P P D G G W G W I V V G A A F I S I G F S Y A F P K A V T V F F K E I Q Q I F H T T Y S E I A W I S S I M L A V M Y A G G P V S S V L V N K Y G S R P V V I A G G L L C C L G M V L A S F S S S V V Q L Y L T M G F I T G L G L A F N L Q P A L T I I G K Y F Y R K R P M A N G L A M A G S P V F L S S L A P F N Q Y L F N T F G W K G S F L I L G S L L L N A C V A G S L M R P L G P N Q T T S K S K N K T G K T E D D S S P K K I K T K K S T W E K V N K Y L D F S L F K H R G F L I Y L S G N V I M F L G F F A P I I F L A P Y A K D Q G I D E Y S A A F L L S V M A F V D M F A R P S V G L I A N S K Y I R P R I Q Y F F S F A I M F N G V C H L L C P L A Q D Y T S L V L Y A V F F G L G F G S V S S V L F E T L M D L V G A P R F S S A V G L V T I V E C G P V L L G P P L A G K L V D L T G E Y K Y M Y M S C G A I V V A A S V W L L I G N A I N Y R L L A K E R K E E N A R Q K T R E S E P L S K S K H S E D V N V K V S N A Q S V T S E R E T N I
PTM type	X-O-glycosylation X-Phosphorylation X-Phosphorylation X-Ubiquitination X-Ubiquitination X: Amino Acid

O-glycosylation
Serine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC16A7			[1], [2]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	465
Experimental Method	Co-Immunoprecipitation
Detailed Description	O-linked Glycosylation at SLC16A7 Serine 465 has the potential to affect its expression or activity.
Phosphorylation
Serine	15 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	.			[3]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	33
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 33 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC16A7			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	177
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 177 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC16A7			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	183
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 183 has the potential to affect its expression or activity.
PTM Phenomenon4	Have the potential to influence SLC16A7			[4]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	193
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 193 has the potential to affect its expression or activity.
PTM Phenomenon5	Have the potential to influence SLC16A7			[5], [6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	218
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 218 has the potential to affect its expression or activity.
PTM Phenomenon6	Have the potential to influence SLC16A7			[5], [6]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	219
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 219 has the potential to affect its expression or activity.
PTM Phenomenon7	Have the potential to influence SLC16A7			[7], [8]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	240
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 240 has the potential to affect its expression or activity.
PTM Phenomenon8	Have the potential to influence SLC16A7			[9]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	281
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 281 has the potential to affect its expression or activity.
PTM Phenomenon9	Have the potential to influence SLC16A7			[5], [10]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	448
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 448 has the potential to affect its expression or activity.
PTM Phenomenon10	Have the potential to influence SLC16A7			[11], [12]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	452
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 452 has the potential to affect its expression or activity.
PTM Phenomenon11	Have the potential to influence SLC16A7			[13], [14]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	454
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 454 has the potential to affect its expression or activity.
PTM Phenomenon12	Have the potential to influence SLC16A7			[13], [14]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	457
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 457 has the potential to affect its expression or activity.
PTM Phenomenon13	Have the potential to influence SLC16A7			[15], [16]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	465
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 465 has the potential to affect its expression or activity.
PTM Phenomenon14	Have the potential to influence SLC16A7			[17], [18]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	469
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 469 has the potential to affect its expression or activity.
PTM Phenomenon15	Have the potential to influence SLC16A7			[5], [18]
Role of PTM	Potential impacts
Modified Residue	Serine	Modified Location	472
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Serine 472 has the potential to affect its expression or activity.
Threonine	3 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	Have the potential to influence SLC16A7			[12], [19]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	445
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Threonine 445 has the potential to affect its expression or activity.
PTM Phenomenon2	Have the potential to influence SLC16A7			[5], [18]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	471
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Threonine 471 has the potential to affect its expression or activity.
PTM Phenomenon3	Have the potential to influence SLC16A7			[17], [18]
Role of PTM	Potential impacts
Modified Residue	Threonine	Modified Location	476
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Threonine 476 has the potential to affect its expression or activity.
Tyrosine	1 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	.			[3]
Role of PTM	Potential impacts
Modified Residue	Tyrosine	Modified Location	34
Experimental Method	Co-Immunoprecipitation
Detailed Description	Phosphorylation at SLC16A7 Tyrosine 34 has the potential to affect its expression or activity.
Ubiquitination
Lysine	6 PTM Phenomena Related to This Residue		Click to Show/Hide the Full List
PTM Phenomenon1	.			[3]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	221
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC16A7 Lysine 221 has the potential to affect its expression or activity.
PTM Phenomenon2	.			[3]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	444
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC16A7 Lysine 444 has the potential to affect its expression or activity.
PTM Phenomenon3	.			[3]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	453
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC16A7 Lysine 453 has the potential to affect its expression or activity.
PTM Phenomenon4	.			[3]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	455
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC16A7 Lysine 455 has the potential to affect its expression or activity.
PTM Phenomenon5	.			[3]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	455
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC16A7 Lysine 455 has the potential to affect its expression or activity.
PTM Phenomenon6	Have the potential to influence SLC16A7			[20]
Role of PTM	Potential impacts
Modified Residue	Lysine	Modified Location	463
Experimental Method	Co-Immunoprecipitation
Detailed Description	Ubiquitination at SLC16A7 Lysine 463 has the potential to affect its expression or activity.

References
1	Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease. J Pathol. 2017 Sep;243(1):78-88.
2	Synthesis of a Highly Azide-Reactive and Thermosensitive Biofunctional Reagent for Efficient Enrichment and Large-Scale Identification of O-GlcNAc Proteins by Mass Spectrometry. Anal Chem. 2017 Jun 6;89(11):5810-5817.
3	ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins. Nucleic Acids Res. 2018;46(D1):D901-D910.
4	Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. Mol Cell Proteomics. 2017 Apr;16(4):663-679.
5	Robust, Reproducible, and Economical Phosphopeptide Enrichment Using Calcium Titanate. J Proteome Res. 2019 Mar 1;18(3):1411-1417.
6	MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene. 2018 Aug;37(33):4518-4533.
7	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
8	Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. Proteomics. 2017 Nov;17(22):10.1002/pmic.201700214.
9	Quantitative global phosphoproteomics of human umbilical vein endothelial cells after activation of the Rap signaling pathway. Mol Biosyst. 2013 Apr 5;9(4):732-49.
10	Global phosphoproteomics of CCR5-tropic HIV-1 signaling reveals reprogramming of cellular protein production pathways and identifies p70-S6K1 and MK2 as HIV-responsive kinases required for optimal infection of CD4+ T cells. Retrovirology. 2018 Jul 3;15(1):44.
11	Tip-Based Fractionation of Batch-Enriched Phosphopeptides Facilitates Easy and Robust Phosphoproteome Analysis. J Proteome Res. 2018 Jan 5;17(1):46-54.
12	Defeating Major Contaminants in Fe3+- Immobilized Metal Ion Affinity Chromatography (IMAC) Phosphopeptide Enrichment. Mol Cell Proteomics. 2018 May;17(5):1028-1034.
13	Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition. Blood. 2017 Jan 12;129(2):e1-e12.
14	Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3175-3180.
15	Protein kinase C-alpha interaction with F0F1-ATPase promotes F0F1-ATPase activity and reduces energy deficits in injured renal cells. J Biol Chem. 2015 Mar 13;290(11):7054-66.
16	Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 2014 Sep 11;8(5):1583-94.
17	An integrated strategy for highly sensitive phosphoproteome analysis from low micrograms of protein samples. Analyst. 2018 Jul 23;143(15):3693-3701.
18	A Methodological Assessment and Characterization of Genetically-Driven Variation in Three Human Phosphoproteomes. Sci Rep. 2018 Aug 14;8(1):12106.
19	HIV-1 Activates T Cell Signaling Independently of Antigen to Drive Viral Spread. Cell Rep. 2017 Jan 24;18(4):1062-1074.
20	Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 2011 Oct 21;44(2):325-40.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Post-Translational Modifications

Visitor Map

Correspondence